$9.11
0.55% today
Nasdaq, Apr 03, 06:36 pm CET
ISIN
US68404V1008
Symbol
OPTN

OptiNose, Inc. Stock price

$9.16
+3.89 73.81% 1M
-0.90 8.96% 6M
+2.48 37.13% YTD
-11.99 56.69% 1Y
-31.34 77.38% 3Y
-53.69 85.43% 5Y
-275.84 96.79% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.01 0.11%
ISIN
US68404V1008
Symbol
OPTN
Sector

Key metrics

Market capitalization $92.74m
Enterprise Value $137.21m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.75
P/S ratio (TTM) P/S ratio 1.19
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 10.19%
Revenue (TTM) Revenue $78.23m
EBIT (operating result TTM) EBIT $-16.32m
Free Cash Flow (TTM) Free Cash Flow $-44.96m
Cash position $84.49m
EPS (TTM) EPS $-2.93
P/E forward negative
P/S forward 0.93
EV/Sales forward 1.37
Short interest 3.10%
Show more

Is OptiNose, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

OptiNose, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a OptiNose, Inc. forecast:

3x Hold
100%

Analyst Opinions

3 Analysts have issued a OptiNose, Inc. forecast:

Hold
100%

Financial data from OptiNose, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
78 78
10% 10%
100%
- Direct Costs 7.53 7.53
15% 15%
10%
71 71
14% 14%
90%
- Selling and Administrative Expenses 83 83
5% 5%
106%
- Research and Development Expense 3.86 3.86
27% 27%
5%
-16 -16
28% 28%
-20%
- Depreciation and Amortization 0.30 0.30
25% 25%
0%
EBIT (Operating Income) EBIT -16 -16
28% 28%
-21%
Net Profit -22 -22
39% 39%
-28%

In millions USD.

Don't miss a Thing! We will send you all news about OptiNose, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

OptiNose, Inc. Stock News

Neutral
Business Wire
13 days ago
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of OptiNose, Inc. (NasdaqGS: OPTN) to Paratek Pharmaceuticals. Under the terms of the proposed transaction, shareholders of OptiNose will receive $9.00 per share in cash, plus up to $5.00 per share in cont...
Neutral
GlobeNewsWire
13 days ago
NEW YORK, March 21, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Neutral
GlobeNewsWire
14 days ago
MONSEY, N.Y., March 20, 2025 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of OptiNose, Inc. (Nasdaq: OPTN) (“OptiNose”) to Paratek Pharmaceuticals (“Paratek”) for $9.00 per share in cash, plus a contingent value right (“CVR”) worth $5.00 per share payable in the event that certain net revenue milestones are achieved by OptiNose's fla...
More OptiNose, Inc. News

Company Profile

OptiNose, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA.

Head office United States
CEO Ramy Mahmoud
Employees 128
Founded 2000
Website www.optinose.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today